Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
CYP2C19 encodes a member of the cytochrome P450 superfamily of enzymes. Additionally we are shipping CYP2C19 Antibodies (33) and CYP2C19 Kits (19) and many more products for this protein.
Showing 3 out of 3 products:
In addition to the CYP2C19 genotype as predictive factors.
no association was identified between the CYP2C19()2 variant and the development of coronary in-stent restenosis.
CYP2C19 genetic polymorphisms had significant influence on the antiplatelet effect of clopidogrel and clinical outcomes in patients with intracranial aneurysms treated with stent-assisted coiling.
The ultrarapid-metabolizing *17 allele of CYP2C19 (OMIM 124020), which is common in Europeans and Africans and rare in Asians, results in higher circulating concentrations of VNO. We hypothesized that LTRs with the *17 allele would have an increased risk for voriconazole-associated SCC (show CYP11A1 Proteins).
This gastric juice-based real-time PCR assay is a more accurate method for detecting H. pylori infection, clarithromycin susceptibility and CYP2C19 polymorphisms. The method may be employed to inform the choice of proton pump inhibitor (PPI), clarithromycin and amoxicillin treatment for tailored H. pylori eradication therapy
This study showed that distinct genetic markers were associated with phenotype-specific PHT-induced severe cutaneous adverse drug reactions. HLA-B*13:01, HLA-B*56:02/04, and CYP2C19*3 were potential genetic markers of phenytoin-induced drug rash with eosinophilia and systemic symptoms/drug hypersensitivity syndrome in Thai patients.
The present study aimed to assess the effects of CYP2C19 gene polymorphisms on proton pump inhibitor (PPI), amoxicillin, and levofloxacin triple therapy for Helicobacter pylori (Hp) eradication.
efficacy of clopidogrel for the prevention of ischemic stroke in post-coronary stent patients may be reduced by the insufficiency of the CYP2C19 gene
These data highlight the potential relevance of CYP2C19 pharmacogenetics in influencing NorEND concentrations in tamoxifen-treated patients, which may influence treatment outcomes
We compared the carrier frequency of Cytochrome P450 Enzymes and Transport Proteins markers among the Russian population living in Moscow with Dagestan ethnic groups. Statistically significant differences for the following gene polymorphisms: CYP2C19*17, CYP2C9 (show CYP2C9 Proteins)*3, ABCB1 (show ABCB1 Proteins) (C3435T), SLCO1B1 (show SLCO1B1 Proteins)*5 were found between the Russian population and the three ethnic groups of the Dagestan republic.
This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and is known to metabolize many xenobiotics, including the anticonvulsive drug mephenytoin, omeprazole, diazepam and some barbiturates. Polymorphism within this gene is associated with variable ability to metabolize mephenytoin, known as the poor metabolizer and extensive metabolizer phenotypes. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24.
cytochrome P450 2C
, (R)-limonene 6-monooxygenase
, (S)-limonene 6-monooxygenase
, (S)-limonene 7-monooxygenase
, S-mephenytoin 4-hydroxylase
, cytochrome P-450 II C
, cytochrome P450 2C19
, cytochrome P450, subfamily IIC (mephenytoin 4-hydroxylase), polypeptide 19
, cytochrome P450-11A
, cytochrome P450-254C
, flavoprotein-linked monooxygenase
, mephenytoin 4'-hydroxylase
, mephenytoin 4-hydroxylase
, microsomal monooxygenase
, xenobiotic monooxygenase